Indivior Pharmaceuticals Inc

INDV

$36.00

Updated: 25/09/2026, 09:57:37

Market Cap

$4.49B

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Country

Stock valuation chart

One-year closing share-price history for INDV

Company Profile

Indivior Pharmaceuticals Inc. operates as a holding company, primarily engaged in the research, production, and distribution of buprenorphine-based prescription medications designed to treat opioid dependence. Its product lineup features key pharmaceuticals such as Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company organizes its business into several geographical regions: the United States, the United Kingdom, and the broader international market. Established on September 26, 2014, its corporate headquarters are located in North Chesterfield, Virginia.

USD

NASDAQ

CEO: Joseph J. Ciaffoni

Employees: 833

https://www.indivior.com

Asset Summaries

Latest generated summaries for INDV

No summaries found.

Detailed business

Structured knowledge from the latest official annual filing.

No official annual filing has completed ingestion for this company yet. The filing worker processes major-index companies incrementally and never repeats a completed fiscal year.

Full company information

Latest profile, trading, valuation, and identifier data stored for INDV.

Share price: $36.00
Market cap: $4.49B
Exchange: NASDAQ
Currency: USD
CEO: Joseph J. Ciaffoni
Employees: 833
IPO date: 29/12/2014
Beta: 1.113
Last dividend: $0.00
Day range: $35.59 – $36.28
52-week range: $22.56 – $42.81
1-day performance: 0.25%
1-year performance: 59.57%
Current drawdown (1Y): -15.91%
CIK: 0001625297
CUSIP: 45579U109
ISIN: US45579U1097
Created: 07/12/2025, 04:43:36
Last update: 25/09/2026, 09:57:37

Track Indivior Pharmaceuticals Inc with an AI analyst

See which prediction-market events move INDV, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.

Create a free account See what the world decides next

Free forever to follow AlphaBrain’s AI strategies. No card required.

Latest Database News

News linked to INDV from your Railway `news_articles` table.

Indivior's Chief Scientific Officer Sold Over 18,000 Company Shares. Should Investors Worry?

Fool - Investing News • STOCK • 14/06/2026, 01:45:47

5 Top-Ranked Efficient Stocks Beating Industry Peers on Key Metrics

Zacks Investment Research • STOCK • 02/06/2026, 11:20:55

Why a Fund Made a $143 Million Bet on Indivior With Shares Up a Staggering 200%

Fool - Investing News • STOCK • 30/05/2026, 16:57:39

Survey of Correctional Facility Staff: Monthly Opioid Treatment Shot May Help Reduce Medication Misuse

GlobeNewsWire • STOCK • 16/04/2026, 16:30:00

National Survey Finds Only 58% of U.S. Correctional Facilities Offer Medications for Opioid Use Disorder

GlobeNewsWire • STOCK • 17/03/2026, 13:02:00

Indivior Pharmaceuticals: A Leader in Opioid Use Disorder Treatment

Market Data • Market Data • 12/03/2026, 19:00:02

New Study Shows Adherence to Monthly Injectable Buprenorphine Linked to Lower Healthcare Utilization and Costs in Opioid Use Disorder

GlobeNewsWire • STOCK • 11/03/2026, 10:00:00